Nisha Pandey

Health and Me

FDA Approves Targeted Cancer Drug As First-Line Treatment For CLL That Cuts Progression Risk By 80%

The US Food and Drug Administration (FDA) has approved pirtobrutinib as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a known deletion of chromosome 17p.

The approval expands the use of the targeted cancer drug, which was previously approved for certain patients whose CLL or SLL had returned or stopped responding to earlier treatment. It is developed by Eli Lilly and Company and will be sold under the brand name Jaypirca.

<a href="https://www.healthandme.com/health-news/us-fda-recalls-india-made-bp-drug-for-the-second-time-in-3-months-heres-why-article-156243338" data-type="tilCustomLink">CLL</a> is a type of blood cancer in which the bone marrow produces too many abnormal B lymphocytes, a type of white blood cell. These abnormal cells can build up in the blood, bone marrow and lymph nodes.

SLL is closely associated with CLL, but the cancer cells are found mainly in the lymph nodes. CLL can progress slowly in some people, while others may develop more aggressive disease.

Pirtobrutinib is a Bruton tyrosine kinase (BTK) inhibitor, a type of targeted therapy. BTK is a protein that helps B cells receive signals needed for their growth and survival. By blocking BTK, pirtobrutinib interferes with signals that cancerous B cells depend on.

Unlike older covalent <a href="https://www.healthandme.com/health-news/us-waives-100-tariff-on-indian-specialty-medicines-which-drugs-qualify-article-156244575" data-type="tilCustomLink">BTK inhibitors</a>, pirtobrutinib is a non-covalent, reversible BTK inhibitor, meaning it binds to BTK differently.

A dose of 200 mg once a day is recommended for newly diagnosed patients covered by this approval. It should be taken until the cancer progresses or side effects become severe.

Also read: <a href="https://www.healthandme.com/health-news/2-indians-charged-in-us-over-fake-ozempic-scheme-how-to-spot-counterfeit-glp-1-drugs-article-156255791" data-type="tilCustomLink">2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs</a>

<h2>Findings From Pirtobrutinib's Trial</h2>

The FDA based its decision on the BRUIN CLL-313 trial, which included 282 adults with previously untreated CLL or SLL without a 17p deletion.

Participants were randomly assigned to receive either <a href="https://www.healthandme.com/health-news/from-365-shots-to-52-how-could-lillys-newly-approved-weekly-insulin-injection-change-diabetes-care-article-156238125" data-type="tilCustomLink">pirtobrutinib</a> or the chemotherapy combination bendamustine plus rituximab.

After a median follow-up of 28 months, the median progression-free survival could not yet be calculated for patients receiving pirtobrutinib because enough disease-progressing events had not occurred. In the bendamustine-rituximab group, median progression-free survival was 33.5 months.

The risk of disease progression or death was 80% lower with pirtobrutinib than with bendamustine plus rituximab in the trial, based on the reported hazard ratio of 0.20.

However, overall survival data are still not 100% reliable. There were 13 deaths at the time of the primary analysis - three in the pirtobrutinib group and 10 in the comparison group.

Also read: <a href="https://www.healthandme.com/fitness/21-in-80-weeks-lancet-study-finds-lillys-retatrutide-delivers-one-of-the-biggest-weight-losses-ever-article-156249026" data-type="tilCustomLink">21% In 80 Weeks: Lancet Study Finds Lilly’s Retatrutide Delivers One Of The Biggest Weight Losses Ever</a>

Fatty Liver Explained: Causes, Symptoms, Treatment, Reversal & Who Is at Risk

The most common non-laboratory side effects reported with pirtobrutinib included:

<ul><li>Upper respiratory tract infections</li><li>Rash</li><li>COVID-19</li></ul>

According to the <a href="https://www.healthandme.com/health-news/485-inactive-chemicals-in-us-pesticide-products-linked-to-breast-cancer-article-156238067" data-type="tilCustomLink">FDA</a>, side effects also include infections, bleeding, reduced blood cell counts, abnormal heart rhythms, other cancers, liver toxicity and harm to an unborn baby. Serious adverse reactions occurred in 28% of patients receiving pirtobrutinib in the trial.

The approval gives eligible people with previously untreated CLL or SLL another targeted treatment option that can be taken as a daily oral medicine.

Jennifer A. Woyach, MD, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center, said, “This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile.”

The FDA's decision applies specifically to adults with previously untreated CLL or SLL without a known 17p deletion. It therefore does not mean that pirtobrutinib is automatically the first treatment for every person newly diagnosed with CLL.

Health Conditions A-Z

health

fda-approves-targeted-cancer-drug-as-first-line-treatment-for-cll-that-cuts-progression-risk-by-80

chronic lymphocytic leukaemia

small lymphocytic lymphoma

pirtobrutinib

pirtobrutinib side effects

jaypirca

us food and drug administration

eli lilly and company

innovations-in-structural-heart-care-the-shift-towards-minimally-invasive-therapies

Innovations in Structural Heart Care: The Shift Towards Minimally Invasive Therapies

can-dim-light-or-screen-glare-during-sleep-stiffen-your-arteries-what-the-science-says

Can Dim Light or Screen Glare During Sleep Stiffen Your Arteries? What the Science Says

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

The US Food and Drug Administration (FDA) has approved pirtobrutinib as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a known deletion of chromosome 17p.The approval expands the use of the targeted cancer drug, which was previously approved for certain patients whose CLL or SLL had returned or stopped responding to earlier treatment. It is developed by Eli Lilly and Company and will be sold under the brand name Jaypirca.More About PirtobrutinibCLL is a type of blood cancer in which the bone marrow produces too many abnormal B lymphocytes, a type of white blood cell. These abnormal cells can build up in the blood, bone marrow and lymph nodes. SLL is closely associated with CLL, but the cancer cells are found mainly in the lymph nodes. CLL can progress slowly in some people, while others may develop more aggressive disease.Pirtobrutinib is a Bruton tyrosine kinase (BTK) inhibitor, a type of targeted therapy. BTK is a protein that helps B cells receive signals needed for their growth and survival. By blocking BTK, pirtobrutinib interferes with signals that cancerous B cells depend on.Unlike older covalent BTK inhibitors, pirtobrutinib is a non-covalent, reversible BTK inhibitor, meaning it binds to BTK differently.A dose of 200 mg once a day is recommended for newly diagnosed patients covered by this approval. It should be taken until the cancer progresses or side effects become severe.Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 DrugsFindings From Pirtobrutinib's TrialThe FDA based its decision on the BRUIN CLL-313 trial, which included 282 adults with previously untreated CLL or SLL without a 17p deletion.Participants were randomly assigned to receive either pirtobrutinib or the chemotherapy combination bendamustine plus rituximab.After a median follow-up of 28 months, the median progression-free survival could not yet be calculated for patients receiving pirtobrutinib because enough disease-progressing events had not occurred. In the bendamustine-rituximab group, median progression-free survival was 33.5 months.The risk of disease progression or death was 80% lower with pirtobrutinib than with bendamustine plus rituximab in the trial, based on the reported hazard ratio of 0.20.However, overall survival data are still not 100% reliable. There were 13 deaths at the time of the primary analysis - three in the pirtobrutinib group and 10 in the comparison group.Also read: 21% In 80 Weeks: Lancet Study Finds Lilly’s Retatrutide Delivers One Of The Biggest Weight Losses EverPirtobrutinib's Side Effects         The most common non-laboratory side effects reported with pirtobrutinib included:Upper respiratory tract infectionsRashCOVID-19According to the FDA, side effects also include infections, bleeding, reduced blood cell counts, abnormal heart rhythms, other cancers, liver toxicity and harm to an unborn baby. Serious adverse reactions occurred in 28% of patients receiving pirtobrutinib in the trial.The approval gives eligible people with previously untreated CLL or SLL another targeted treatment option that can be taken as a daily oral medicine.Jennifer A. Woyach, MD, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center, said, “This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile.”The FDA's decision applies specifically to adults with previously untreated CLL or SLL without a known 17p deletion. It therefore does not mean that pirtobrutinib is automatically the first treatment for every person newly diagnosed with CLL.

fda approves targeted cancer drug as first-line treatment for cll that cuts progression risk by 80%

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

FDA Approves Targeted Cancer Drug As First-Line Treatment For CLL That Cuts Progression Risk By 80%

‘American Covid’ Strain Drives 50% Surge in UK Hospital Admissions: XFG Symptoms to Know

Robotics Set to Transform Every Medical Specialty, From Diagnostics to Therapy in India: Jitendra Singh

Brooke Eby Dies At 37 After Chronicling Her ALS Journey For Four Years

Health Conditions A-Z

FDA Approves Targeted Cancer Drug As First-Line Treatment For CLL That Cuts Progression Risk By 80%

Innovations in Structural Heart Care: The Shift Towards Minimally Invasive Therapies

Can Dim Light or Screen Glare During Sleep Stiffen Your Arteries? What the Science Says